X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
single-arm (597) 597
index medicus (375) 375
open-label (345) 345
oncology (330) 330
humans (274) 274
chemotherapy (185) 185
immunotherapy (184) 184
cancer (181) 181
multicenter (160) 160
clinical trials (111) 111
care and treatment (97) 97
female (96) 96
pembrolizumab (96) 96
male (89) 89
metastasis (89) 89
cisplatin-ineligible patients (82) 82
patients (81) 81
treatment outcome (80) 80
nivolumab (75) 75
pharmacology & pharmacy (73) 73
therapy (70) 70
hematology (69) 69
metastatic urothelial carcinoma (68) 68
middle aged (68) 68
aged (67) 67
urothelial carcinoma (65) 65
phase-ii (64) 64
bladder cancer (63) 63
cancer therapies (63) 63
review (63) 63
tumors (62) 62
medical research (59) 59
cell lung-cancer (58) 58
phase-ii trial (57) 57
urology & nephrology (57) 57
analysis (56) 56
drug therapy (56) 56
lung cancer (56) 56
mutation (53) 53
research (53) 53
antineoplastic agents - therapeutic use (52) 52
carcinoma (52) 52
safety (51) 51
1st-line treatment (50) 50
double-blind (50) 50
adult (49) 49
immune checkpoint (49) 49
immunology (48) 48
immunotherapy - methods (48) 48
medicine & public health (48) 48
cisplatin (46) 46
crizotinib (45) 45
health aspects (44) 44
survival (43) 43
antibodies, monoclonal - therapeutic use (40) 40
lung cancer, non-small cell (40) 40
lymphomas (38) 38
trial (38) 38
atezolizumab (37) 37
acquired-resistance (36) 36
biomarkers (36) 36
prognosis (36) 36
lung neoplasms - drug therapy (35) 35
medicine, research & experimental (35) 35
pd-1 blockade (35) 35
pd-l1 (35) 35
apoptosis (34) 34
ceritinib (34) 34
development and progression (34) 34
disease-free survival (33) 33
surgery (33) 33
advanced melanoma (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
medicine, experimental (32) 32
melanoma (32) 32
metastases (32) 32
respiratory system (32) 32
carcinoma, non-small-cell lung - drug therapy (31) 31
non-small cell lung cancer (31) 31
pd-1 (31) 31
phase-iii trial (31) 31
tyrosine (31) 31
clinical trials as topic (30) 30
cytotoxicity (30) 30
anaplastic lymphoma kinase (29) 29
bladder-cancer (29) 29
follow-up (29) 29
genetic aspects (29) 29
neoplasms. tumors. oncology. including cancer and carcinogens (29) 29
usage (29) 29
alectinib (28) 28
phase-2 trial (28) 28
solid tumors (28) 28
aged, 80 and over (27) 27
alk (27) 27
animals (27) 27
efficacy (27) 27
leukemia (27) 27
molecular targeted therapy (27) 27
t-cells (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (700) 700
Chinese (16) 16
German (16) 16
Japanese (12) 12
French (3) 3
Spanish (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 2019, Volume 133, Issue 11, pp. 1201 - 1204
Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment... 
BTK | MULTICENTER | INHIBITION | SINGLE-ARM | HEMATOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1685 - 1694
Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in... 
MULTICENTER | VARIANTS | ONCOLOGY | PD-1 BLOCKADE | MUTATIONAL LANDSCAPE | SENSITIVITY | SINGLE-ARM | NIVOLUMAB | CARCINOMA | TUMORS | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2693 - 2701
PurposeIn patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease... 
ALK | MULTICENTER | SOLID TUMORS | ONCOLOGY | CERITINIB | PHASE-1 TRIAL | CRIZOTINIB | OPEN-LABEL | WHOLE-BODY | SINGLE-ARM | CHEMOTHERAPY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1199 - 1206
PurposeAdvanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase... 
GENE | ONCOLOGY | CERITINIB | CRIZOTINIB | OPEN-LABEL | SINGLE-ARM | INHIBITOR | IDENTIFICATION | FUSION VARIANT | NSCLC PATIENTS | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e397 - e399
Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | SINGLE-ARM | CISPLATIN-INELIGIBLE PATIENTS
Journal Article
Journal Article
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 02/2018, Volume 15, Issue 2, pp. 73 - 74
2017 saw the publication of clinical trial data and the approval of new treatment approaches for metastatic urothelial carcinoma. Pembrolizumab is now a... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | SINGLE-ARM | CISPLATIN-INELIGIBLE PATIENTS | CHEMOTHERAPY
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 03/2019, Volume 25, Issue 5, pp. 1486 - 1493
Purpose: Cellular therapy is an emerging cancer treatment modality, but its application to epithelial cancers has been limited. This clinical trial evaluated... 
HEAD | MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | IMMUNOTHERAPY | RECURRENT | SQUAMOUS-CELL CARCINOMA | PHASE-II | CERVICAL-CANCER | SINGLE-ARM | NIVOLUMAB
Journal Article
by Kim, KH and Cho, J and Ku, BM and Koh, J and Sun, JM and Lee, SH and Ahn, JS and Cheon, J and Min, YJ and Park, SH and Park, K and Ahn, MJ and Shin, EC
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 04/2019, Volume 25, Issue 7, pp. 2144 - 2154
Purpose: To investigate blood-based dynamic biomarkers that predict responses to anti-programmed cell death protein 1 (PD-1) therapy in solid tumors.... 
BIOMARKERS | MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | SAFETY | PD-1 BLOCKADE | OPEN-LABEL | SINGLE-ARM | NIVOLUMAB | IMMUNE-CHECKPOINT BLOCKADE | CHEMOTHERAPY
Journal Article
EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 03/2017, Volume 73, pp. 1 - 8
Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of cancer treatment but are associated with several immune-related... 
Anti-CTLA4 | Neurological adverse events | GUILLAIN-BARRE-SYNDROME | Immune checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | CELL LUNG-CANCER | PHASE-II TRIAL | ONCOLOGY | LONG-TERM SAFETY | PRETREATED ADVANCED MELANOMA | Anti-PD1 | RESISTANT PROSTATE-CANCER | CTLA4 BLOCKADE | IPILIMUMAB TREATMENT
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2677 - 2679
Journal Article
Zhonghua zhong liu za zhi [Chinese journal of oncology], ISSN 0253-3766, 01/2018, Volume 40, Issue 1, pp. 58 - 62
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 12, pp. 1288 - 1296
Journal Article
International Journal of Recent Technology and Engineering, 05/2019, Volume 8, Issue 1, pp. 2112 - 2115
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 2, pp. 208 - 215
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 17, pp. 1479 - 1489
PURPOSE Anti-programmed death-1 (PD-1) monotherapy induces a high response rate in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | PD-1 BLOCKADE | BRENTUXIMAB VEDOTIN | MULTICOHORT | PHASE-II | CELL TRANSPLANTATION | SINGLE-ARM | NIVOLUMAB | T-CELLS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 35, pp. 3504 - 3519
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic hematopoietic cell transplantation, result in an overall survival... 
YOUNG-ADULTS | HYPER-CVAD | ONCOLOGY | INOTUZUMAB OZOGAMICIN | TERM-FOLLOW-UP | PHASE-II | RELAPSE-FREE SURVIVAL | STEM-CELL TRANSPLANTATION | SINGLE-ARM | MINIMAL RESIDUAL DISEASE | MURINE XENOGRAFT MODELS
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2018, Volume 13, Issue 11, pp. 1619 - 1622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.